Your browser doesn't support javascript.
loading
A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Barfield, Robyn M; Kim, Yun Cheol; Chuprakov, Stepan; Zhang, Fangjiu; Bauzon, Maxine; Ogunkoya, Ayodele O; Yeo, Dominick; Hickle, Colin; Pegram, Mark D; Rabuka, David; Drake, Penelope M.
Afiliação
  • Barfield RM; Catalent Biologics, Emeryville, California.
  • Kim YC; Catalent Biologics, Emeryville, California.
  • Chuprakov S; Catalent Biologics, Emeryville, California.
  • Zhang F; Catalent Biologics, Emeryville, California.
  • Bauzon M; Catalent Biologics, Emeryville, California.
  • Ogunkoya AO; Catalent Biologics, Emeryville, California.
  • Yeo D; Catalent Biologics, Emeryville, California.
  • Hickle C; Catalent Biologics, Emeryville, California.
  • Pegram MD; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Rabuka D; Catalent Biologics, Emeryville, California.
  • Drake PM; Catalent Biologics, Emeryville, California. penelope.drake@catalent.com.
Mol Cancer Ther ; 19(9): 1866-1874, 2020 09.
Article em En | MEDLINE | ID: mdl-32651200
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Imunoconjugados / Trastuzumab / Ado-Trastuzumab Emtansina / Maitansina Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Imunoconjugados / Trastuzumab / Ado-Trastuzumab Emtansina / Maitansina Idioma: En Ano de publicação: 2020 Tipo de documento: Article